The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)

Cancer

Volumn 119, Issue 20, 2013, Pages 3636-3643

  Aggarwal, Rahul ^a   Halabi, Susan ^b   Kelly, William Kevin ^c   George, Daniel ^b   Mahoney, John F ^d   Millard, Frederick ^e   Stadler, Walter M ^f   Morris, Michael J ^g   Kantoff, Philip ^h   Monk, J Paul ⁱ   Carducci, Michael ^j   Small, Eric J ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

androgen antagonists; chemotherapy; ketoconazole; prostatic neoplasms; steroid 17 alpha hydroxylase

Indexed keywords

ANDROGEN; BEVACIZUMAB; DOCETAXEL; KETOCONAZOLE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBJECTIVE RESPONSE RATE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; VALIDATION STUDY;

ANDROGEN ANTAGONISTS; CHEMOTHERAPY; KETOCONAZOLE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

AGED; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; KETOCONAZOLE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PREDNISONE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84885179814     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28285     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Tannock IF, de Wilt R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520. (Pubitemid 39315318)
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010; 376: 1147-1154.
5. Ryan CJ, Smith MR, Fong L, et al. Phase 1 clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010; 28: 1481-1488.
6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
7. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375: 1437-1446.
8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-1197.
9. Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence of cross-resistance? Ann Oncol. 2012; 23: 2943-2948.
10. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N,. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70: 7992-8002.
11. Vasaitis TS, Bruno RD, Njar V,. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011; 125: 23-31.
12. Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C,. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol. 1991; 35: 164-168.
13. Santen RJ, Van Den Bossche H, Symoens J, Brugmans J, DeCoster R,. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983; 57: 732-736. (Pubitemid 13013529)
14. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D,. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983; 71: 1495-1499. (Pubitemid 13098940)
15. Small EJ, Baron AD, Fippin L, Apodaca D,. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157: 1204-1207. (Pubitemid 27130781)
16. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004; 22: 1025-1033. (Pubitemid 41095034)
17. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012; 30: 1534-1540.
18. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467. (Pubitemid 29517916)
19. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232-1237. (Pubitemid 46606398)
20. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
21. Cox DR,. Regression models and life-tables (with discussion). J R Stat Soc. 1972; B34: 187-220.
22. Zou G,. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702-706. (Pubitemid 38405384)
23. Therasse P, Arbuck S, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216. (Pubitemid 30099779)
24. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW,. Effects of novel 17α-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003; 84: 555-562. (Pubitemid 36588809)
25. Aggarwal R, Formaker C, Small EJ, et al. Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPA) [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 4664.